1. Medtech Insight
  2. >>Device Area
  3. >>Surgery
  4. >>Surgical Procedures

Femtosecond Lasers: Expanding The Premium Cataract Surgery Market

Laser Cataract User Survey Shows Strong Initial Uptake

When femtosecond lasers for cataract surgery hit the market in early 2011, it was apparent that that they would bring unprecedented precision to the procedure. The key questions surrounding this emerging field quickly shifted to commercial viability: how would US cataract surgeons and facilities be able to pay for this expensive new technology in a procedure that is reimbursed almost entirely by Medicare, and therefore subject to strict billing limitations? A survey of early laser adopters in the US, detailed below, suggests that surgeons are successfully navigating these regulatory hurdles and incorporating the new lasers into their practices.

Femtosecond (FS) lasers represent the first truly disruptive technology in cataract surgery since the introduction of ultrasonic phacoemulsification in the late 1960s and foldable intraocular lenses (IOLs) in the 1980s. Developments in this arena have come at a rapid pace: laser cataract technology was formally introduced to the ophthalmic community only three years ago, in late 2009, and the first lasers became commercially available in the beginning of 2011. (See Also see "Laser Cataract Surgery: Sorting Out The Business Case" - Medtech Insight, 16 December, 2011..)

Because it became apparent very early on that FS lasers would bring unprecedented precision to cataract surgery, the key questions surrounding this emerging field quickly shifted from clinical and technical...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Surgical Procedures

Bone Surgery Startup Surgify Medical Raises $7.9m

 
• By Natasha Barrow

Surgify Medical’s selective drill tip, Surgify Halo, is “an obvious choice for surgeons,” said Boris Hofmann, head of ZEISS Ventures and lead investor in the company’s series A funding round.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

SS Innovations Files For De Novo For SSi Mantra 3 Surgical Robotic System For Multispecialty Indications

 
• By Marion Webb

SS Innovations announced plans to file a de novo application with the US FDA for its SSi Mantra 3 surgical robot, already approved for marketing in six countries. The Florida-based firm also plans to pursue the CE mark for European commercialization.

California Medtech Firms Resolve Patent Dispute Over Delivery Catheters

 
• By Brian Bossetta

Route 92 says it has reached a settlement with Q’Apel Medical over patent claims concerning its Tenzing delivery catheters.

More from Surgery

California Medtech Firms Resolve Patent Dispute Over Delivery Catheters

 
• By Brian Bossetta

Route 92 says it has reached a settlement with Q’Apel Medical over patent claims concerning its Tenzing delivery catheters.

AAOS 2025 Orthopedic Roundup: J&J Velys UKA, Stryker Mako 4, Materialise, Canary Medical

 
• By Marion Webb

At AAOS, orthopedics players showcased their latest robotic-assisted platforms, power tools, 3D printed technologies and software offerings. This article brings you highlights from interviews Medtech Insight conducted on site with representatives from J&J, Stryker, Materialise and Canary Medical.

Medtronic Presents Data To Boost Hugo’s Odds Of Getting FDA Nod

 
• By Brian Bossetta

Medtronic says results from a recent study on the Hugo robotic-assisted surgery system substantiate its safety and effectiveness for various urological procedures. The company also announced it has submitted the system to the FDA for approval for a urological indication.